Клинический разбор в общей медицине, 2021 The diabetic ketoacidosis (DKA) is the most frequent urgent condition in patients with diabetes mellitus which requires hospitalization and results to mortality. The most common causes of DKA are the presence of concomitant diseases in diabetic patients,
Diana Sh. Avzaletdinova +3 more
doaj +2 more sources
Sodium-glucose co-transporter 2 inhibitors beyond diabetes
Australian Prescriber, 2022 Sodium-glucose co-transporter 2 (SGLT2) inhibitors lower blood glucose by reducing the reabsorption of glucose in the kidney. They are a second-line therapy for type 2 diabetes. During clinical trials it was noticed that SGLT2 inhibitors had favourable effects on cardiovascular and renal disease.
Williams, Dimity L. +2 more
openaire +6 more sources
Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of anti-diabetic agents [PDF]
Drugs in Context, 2014 Although several treatment options are available to reduce hyperglycemia, only about half of individuals with diagnosed diabetes mellitus (DM) achieve recommended glycemic targets.
Eva M Vivian
doaj +2 more sources
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review [PDF]
Cardiovascular Diabetology, 2023 Sodium-glucose co-transporter-2 inhibitors are used in the treatment of diabetes but are also emerging as cardioprotective agents in heart diseases even in the absence of type 2 diabetes.
Julia Hoehlschen +3 more
doaj +3 more sources
Sodium glucose co-transporter 2 inhibitors in patients with resistant hypertension: a case study [PDF]
JRSM Open, 2016 Sodium glucose co-transporter 2 inhibitors lower blood pressure by osmotic diuresis and can be considered in diabetic patients with resistant hypertension.
Amira Obeid +3 more
doaj +2 more sources
Sodium-glucose co-transporter 2 (SGLT2) inhibitors [PDF]
, 2020 peer ...
Mifsud, Simon +3 more
core +4 more sources
The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus [PDF]
, 2022 Sodium-glucose co-transporter-2 (SGLT2) inhibitors offer significant outcome benefits beyond glucose lowering including reduced risk of cardiovascular death, all-cause mortality, major adverse cardiovascular events, hospitalisations for heart failure and
M Evans (7332128) +4 more
core +6 more sources
Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
Frontiers in Pharmacology, 2022 Daniel H. Van Raalte +1 more
doaj +3 more sources
Research advances on renoprotective mechanism of SGLT-2 inhibitors in non-diabetic kidney disease
Linchuang shenzangbing zazhi, 2023 Sodium-glucose linked transporter (SGLT-2) inhibitors are the most emerging glucose-lowering agents. Predominantly expressed in kidney, SGLT-2 is mainly distributed in upper part of proximal tubule.
Feng Liu +3 more
doaj +1 more source
Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus [PDF]
Diabetes & Metabolism Journal, 2022 Background Although cardiovascular outcome trials using sodium-glucose cotransporter-2 inhibitors (SGLT-2i) showed a reduction in risk of 3-point major adverse cardiovascular events (MACE), they did not demonstrate beneficial effects on stroke risk ...
Seung Eun Lee +5 more
doaj +1 more source